Baillie Gifford & Co. Sells 1,266,152 Shares of Moderna, Inc. $MRNA

Key Points

• Baillie Gifford & Co. cut its Moderna stake by 5.8%, selling 1,266,152 shares and leaving it with 20,580,514 shares (about 5.27% of the company) valued at $606,919,000.
• Stephen Hoge, Moderna's president, sold 160,009 shares at an average price of $48.84 for roughly $7.81 million, reducing his ownership by 9.89%; corporate insiders now hold 10.80% of the stock.
• Moderna reported Q results with a loss per share of ($2.11) that beat estimates and revenue of $678 million (down 33.2% YoY), while analysts carry an average rating of "Reduce" and an average price target of $33.87.

Baillie Gifford & Co. reduced its holdings in shares of Moderna, Inc. (NASDAQ:MRNA - Free Report) by 5.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,580,514 shares of the company's stock after selling 1,266,152 shares during the quarter. Baillie Gifford & Co. owned approximately 5.27% of Moderna worth $606,919,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in the business. Invesco Ltd. grew its stake in shares of Moderna by 15.7% during the 3rd quarter. Invesco Ltd. now owns 8,216,163 shares of the company's stock worth $212,223,000 after acquiring an additional 1,115,131 shares in the last quarter. Theleme Partners LLP grew its stake in shares of Moderna by 2.5% during the 3rd quarter. Theleme Partners LLP now owns 8,068,810 shares of the company's stock worth $208,417,000 after acquiring an additional 200,000 shares in the last quarter. Bank of America Corp DE grew its stake in shares of Moderna by 84.3% during the 2nd quarter. Bank of America Corp DE now owns 1,779,309 shares of the company's stock worth $49,091,000 after acquiring an additional 813,974 shares in the last quarter. Jacobs Levy Equity Management Inc. grew its stake in shares of Moderna by 7.7% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,449,931 shares of the company's stock worth $37,452,000 after acquiring an additional 103,981 shares in the last quarter. Finally, Douglas Lane & Associates LLC grew its stake in shares of Moderna by 14.4% during the 4th quarter. Douglas Lane & Associates LLC now owns 1,291,465 shares of the company's stock worth $38,085,000 after acquiring an additional 163,031 shares in the last quarter. 75.33% of the stock is owned by institutional investors.

Insider Buying and Selling at Moderna

In other news, President Stephen Hoge sold 160,009 shares of Moderna stock in a transaction on Monday, February 23rd. The stock was sold at an average price of $48.84, for a total transaction of $7,814,839.56. Following the completion of the sale, the president owned 1,457,427 shares of the company's stock, valued at approximately $71,180,734.68. This trade represents a 9.89% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.80% of the company's stock.

Moderna Stock Performance

Shares of Moderna stock opened at $50.96 on Monday. The business has a fifty day simple moving average of $49.38 and a two-hundred day simple moving average of $37.03. Moderna, Inc. has a 1 year low of $22.28 and a 1 year high of $59.55. The company has a market capitalization of $20.13 billion, a price-to-earnings ratio of -7.01 and a beta of 1.33. The company has a debt-to-equity ratio of 0.07, a current ratio of 3.29 and a quick ratio of 3.22.

Moderna (NASDAQ:MRNA - Get Free Report) last announced its quarterly earnings results on Friday, February 13th. The company reported ($2.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.79) by $0.68. Moderna had a negative return on equity of 30.15% and a negative net margin of 145.16%.The business had revenue of $678.00 million during the quarter, compared to the consensus estimate of $611.14 million. During the same quarter last year, the firm posted ($2.91) EPS. The company's quarterly revenue was down 33.2% on a year-over-year basis. Research analysts forecast that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Ratings Changes

MRNA has been the subject of several analyst reports. TD Cowen reissued a "hold" rating on shares of Moderna in a research note on Thursday, January 29th. Morgan Stanley set a $30.00 target price on shares of Moderna in a research note on Monday, February 16th. Royal Bank Of Canada raised their target price on shares of Moderna from $25.00 to $30.00 and gave the company a "sector perform" rating in a research note on Tuesday, February 17th. Sanford C. Bernstein reissued a "market perform" rating and issued a $45.00 target price on shares of Moderna in a research note on Tuesday, February 17th. Finally, Leerink Partners reissued an "underperform" rating on shares of Moderna in a research note on Friday, January 30th. Two analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and five have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of "Reduce" and an average price target of $33.87.

Moderna Profile

Moderna, Inc is a biotechnology company headquartered in Cambridge, Massachusetts, specializing in messenger RNA (mRNA) therapeutics and vaccines. The company's platform leverages synthetic mRNA to instruct cells to produce proteins that can prevent or treat diseases. Since its founding in 2010, Moderna has advanced from early-stage research into a broad pipeline of vaccine and therapeutic candidates designed to address infectious diseases, rare genetic disorders and chronic illnesses.

Moderna's flagship product is its mRNA-based COVID-19 vaccine, which was the first of its kind to receive emergency use authorization and later full approval in multiple jurisdictions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.